OBSV - ObsEva inks licensing deal with Theramex for commercialization of linzagolix

ObsEva (NASDAQ:OBSV) signed a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in markets outside of the U.S., Canada and Asia. OBSV is entitled to receive royalties of a mid-thirties percentage on commercial sales, which includes the cost of goods sold to Theramex. The deal contains up to €72.75M in upfront and milestone payments, including €5M to be paid at signing, up to €13.75M in development and commercial milestones and up to €54M in sales-based milestones. “This Theramex partnership in Europe, together with our relationship with Syneos Health for the commercialization of linzagolix in the U.S., provides ObsEva with a strong foundation to realize the full value of the linzagolix program,” said Brian O’Callaghan, CEO, ObsEva. Last week, OBSV said the European marketing authorization for linzagolix could be potentially be delayed. Linzagolix is currently under FDA review for heavy menstrual bleeding linked to uterine fibroids.

For further details see:

ObsEva inks licensing deal with Theramex for commercialization of linzagolix